Jiangsu Hengrui Pharmaceuticals

Diversified pharma

600276 · SSE · China

Public Market Listing

600276SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Jiangsu Hengrui Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(116 total)
116Total Assets
0Approved
44Phase 3 / Filed
72Phase 1–2 / Early
60Diseases
Quick filter:
Showing 116 of 116 assets
Target & Modality
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung Cancer
Phase 3
VEGFR2Small molecule
Non-Small Cell Lung CancerHepatocellular Carcinoma
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical CancerHepatocellular CarcinomaGastric CancerNasopharyngeal Carcinoma
Phase 3
CDK4 and CDK6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3Small molecule
Non-Small Cell Lung CancerCervical Cancer
Phase 3
TSLPMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthma
Phase 3
PARP (poly ADP-ribose polymerase), specifically PARP-1Small molecule
Metastatic Castration-Resistant Prostate Cancer
Phase 3
Sodium-glucose cotransporter 2 (SGLT2)Small molecule
Type 2 DiabetesChronic Kidney Disease
Phase 3
Thrombopoietin receptor (TPO-R)Small molecule
Chemotherapy-Induced Thrombocytopenia
Phase 3
Insulin receptor / GLP-1 receptor (combination)Peptide
Type 2 Diabetes
Phase 3
Central dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide)Small molecule
Parkinson's Disease
Phase 3
Mineralocorticoid receptorSmall molecule
Chronic Kidney Disease
Phase 3
Cardiac myosin (inhibitor)
Hypertrophic Cardiomyopathy
Phase 3
PSMA
Metastatic Castration-Resistant Prostate Cancer
Phase 3
KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D · KRAS G12D
Pancreatic Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(143 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (22)
November 2026 (3)
Pyrotinib + Trastuzumab rezetecanPhase 1/2HER2-expressing Advanced Solid Tumors
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
SHR-1681Phase 1/2Malignant Solid Tumors
Est. primary completion 2026-11 · NCT06737731 · CT.gov ↗
What to watch
HRS-1780Phase 2Primary Aldosteronism
Est. primary completion 2026-11 · NCT07470983 · CT.gov ↗
What to watch
December 2026 (19)
Adebrelimab + Pyrotinib + Trastuzumab rezetecanPhase 1/2Advanced Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Adebrelimab + Trastuzumab rezetecanPhase 1/2Ovarian Cancer
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Zeprumetostat + HRS-2189 + HRS-6208 + HRS-5041Phase 1/2Prostate Cancer
Est. primary completion 2026-12 · NCT06568094 · CT.gov ↗
What to watch
SHR-6209 + HRS-6209 + HRS-2189Phase 1/2Breast Cancer
Est. primary completion 2026-12 · NCT06974929 · CT.gov ↗
What to watch
SHR-7787Phase 1/2Advanced Solid Tumors
Est. primary completion 2026-12 · NCT06605222 · CT.gov ↗
What to watch
SHR-3167Phase 2Diabetes Mellitus, Type 2
Est. primary completion 2026-12 · NCT07472725 · CT.gov ↗
What to watch
HRS-7085Phase 2Adult Patients With Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2026-12 · NCT07229950 · CT.gov ↗
What to watch
Safiglipron (HRS-7535)Phase 2Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Est. primary completion 2026-12 · NCT06820099 · CT.gov ↗
What to watch
Notiretatug rezetecan + AdebrelimabPhase 2Advanced Malignant Tumour
Est. primary completion 2026-12 · NCT06915142 · CT.gov ↗
What to watch
AdebrelimabPhase 2NSCLC
Est. primary completion 2026-12 · NCT06844474 · CT.gov ↗
What to watch
SHR-1819Phase 3Seasonal Allergic Rhinitis
Est. primary completion 2026-12 · NCT07688772 · CT.gov ↗
What to watch
Ruzaltatug rezetecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06671379 · CT.gov ↗
What to watch
ivarmacitinibPhase 3Psoriatic Arthritis
Est. primary completion 2026-12-13 · NCT04957550 · CT.gov ↗
What to watch
AdebrelimabPhase 2Biliary Tract Cancer
Est. primary completion 2026-12-30 · NCT06465563 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 2HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Est. primary completion 2026-12-31 · NCT06413745 · CT.gov ↗
What to watch
SHR-1139Phase 2Psoriasis
Est. primary completion 2026-12-31 · NCT07719530 · CT.gov ↗
What to watch
FluzoparibPhase 3Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Est. primary completion 2026-12-31 · NCT04691804 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗
What to watch
HRS-9190Phase 3Neuromuscular Blockade
Est. primary completion 2026-12-31 · NCT07746726 · CT.gov ↗
What to watch
2027 (55)
January 2027 (2)
SHR-4375Phase 1/2Advanced Solid Tumor
Est. primary completion 2027-01 · NCT07298772 · CT.gov ↗
What to watch
RSS0393Phase 3Plaque Psoriasis Subjects
Est. primary completion 2027-01 · NCT07543224 · CT.gov ↗
What to watch
February 2027 (2)
AdebrelimabPhase 1/2Malignant Solid Tumor
Est. primary completion 2027-02 · NCT07136142 · CT.gov ↗
What to watch
HRS-5346Phase 2Lipoprotein Disorder
Est. primary completion 2027-02 · NCT07767513 · CT.gov ↗
What to watch
March 2027 (6)
Notiretatug rezetecan + AdebrelimabPhase 1/2Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-03 · NCT07059221 · CT.gov ↗
What to watch
HRS-4642Phase 1/2Advanced Solid Tumors
Est. primary completion 2027-03 · NCT06520488 · CT.gov ↗
What to watch
ivarmacitinibPhase 2Non-segmental Vitiligo
Est. primary completion 2027-03 · NCT07251595 · CT.gov ↗
What to watch
HRS-1893Phase 2Heart Failure With Preserved Ejection Fraction
Est. primary completion 2027-03 · NCT07269717 · CT.gov ↗
What to watch
SHR-A1912Phase 3Diffuse Large B-cell Lymphoma
Est. primary completion 2027-03 · NCT06929624 · CT.gov ↗
What to watch
RezvilutamidePhase 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Est. primary completion 2027-03 · NCT07241416 · CT.gov ↗
What to watch
April 2027 (2)
ZeprumetostatPhase 2Follicular Lymphoma
Est. primary completion 2027-04 · NCT06368167 · CT.gov ↗
What to watch
SHR-2173Phase 2Primary IgA Nephropathy
Est. primary completion 2027-04 · NCT07354932 · CT.gov ↗
What to watch
May 2027 (4)
SHR-4375Phase 1/2Solid Tumors
Est. primary completion 2027-05 · NCT06764628 · CT.gov ↗
What to watch
ribupatidePhase 2Obesity
Est. primary completion 2027-05 · NCT07458269 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3Ovarian Cancer
Est. primary completion 2027-05 · NCT06828354 · CT.gov ↗
What to watch
Notiretatug rezetecan + AdebrelimabPhase 1/2Advanced Urothelial Carcinoma
Est. primary completion 2027-05-31 · NCT06639347 · CT.gov ↗
What to watch
June 2027 (6)
SHR-9803Phase 1/2Advanced Solid Tumors
Est. primary completion 2027-06 · NCT06906731 · CT.gov ↗
What to watch
SHR-1819Phase 2Moderate-to-severe Atopic Dermatitis
Est. primary completion 2027-06 · NCT07321951 · CT.gov ↗
What to watch
SHR-1139Phase 2Pyoderma Gangrenosum
Est. primary completion 2027-06 · NCT07444684 · CT.gov ↗
What to watch
SHR-2173Phase 2Active Lupus Nephritis
Est. primary completion 2027-06 · NCT07229742 · CT.gov ↗
What to watch
PyrotinibPhase 3Breast Cancer
Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-06-30 · NCT06123494 · CT.gov ↗
What to watch
July 2027 (5)
SHR-1139Phase 2Plaque Psoriasis
Est. primary completion 2027-07 · NCT07758075 · CT.gov ↗
What to watch
Apatinib + AdebrelimabPhase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
SHR4640Phase 2Primary Gout and Hyperuricemia
Est. primary completion 2027-07 · NCT07362355 · CT.gov ↗
What to watch
Safiglipron (HRS-7535)Phase 2Obesity, Overweight
Est. primary completion 2027-07-07 · NCT07497880 · CT.gov ↗
What to watch
Retlirafusp alfaPhase 1/2Relapsed or Advanced Non-small Cell Lung Cancer
Est. primary completion 2027-07-30 · NCT05503888 · CT.gov ↗
What to watch
August 2027 (3)
SHR-1139Phase 2Adult Patients With Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2027-08 · NCT07232576 · CT.gov ↗
What to watch
SHR-2173Phase 2Primary Membranous Nephropathy
Est. primary completion 2027-08 · NCT07289763 · CT.gov ↗
What to watch
HRS-8080Phase 3Locally Advanced Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2027-08 · NCT07024173 · CT.gov ↗
What to watch
September 2027 (4)
HRS-4508Phase 2Solid Tumor
Est. primary completion 2027-09 · NCT07003321 · CT.gov ↗
What to watch
SHR-2173Phase 2Generalized Myasthenia Gravis
Est. primary completion 2027-09 · NCT07622342 · CT.gov ↗
What to watch
SHR-1703Phase 3Asthma With Eosinophilic Phenotype
Est. primary completion 2027-09 · NCT06653322 · CT.gov ↗
What to watch
SHR-A1904Phase 3Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-09-20 · NCT06649292 · CT.gov ↗
What to watch
October 2027 (4)
HRS-4508 + Trastuzumab rezetecanPhase 1/2Solid Tumor
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
Adebrelimab + HRS-4642Phase 1/2Locally Advanced or Metastatic Pancreatic Cancer With
Est. primary completion 2027-10 · NCT07296341 · CT.gov ↗
What to watch
SHR-3167Phase 3Type 2 Diabetes
Est. primary completion 2027-10 · NCT07920939 · CT.gov ↗
What to watch
HRS-5346Phase 2Lipoprotein(a)
Est. primary completion 2027-10-12 · NCT07614984 · CT.gov ↗
What to watch
November 2027 (4)
Rezvilutamide + HRS-5041 + SHR-4394Phase 1/2Prostate Cancer
Est. primary completion 2027-11 · NCT07407283 · CT.gov ↗
What to watch
SHR-1139Phase 2Palmoplantar Pustulosis of Adults
Est. primary completion 2027-11 · NCT07923851 · CT.gov ↗
What to watch
AdebrelimabPhase 2Lung Cancer
Est. primary completion 2027-11 · NCT07241767 · CT.gov ↗
What to watch
SHR-1819Phase 3Adolescents With Moderate-to-severe Atopic Dermatitis
Est. primary completion 2027-11 · NCT07309055 · CT.gov ↗
What to watch
December 2027 (13)
HRS-4508 + SHR-6209 + HRS-6209 + HRS-8080Phase 1/2Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
Est. primary completion 2027-12 · NCT06555068 · CT.gov ↗
What to watch
AdebrelimabPhase 1/2Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-12 · NCT06754930 · CT.gov ↗
What to watch
Adebrelimab + SHR-1501Phase 1/2Patients With Advanced or Metastatic Malignant Tumors
Est. primary completion 2027-12 · NCT07073534 · CT.gov ↗
What to watch
AdebrelimabPhase 1/2Solid Tumor
Est. primary completion 2027-12 · NCT07229586 · CT.gov ↗
What to watch
Retlirafusp alfa + Adebrelimab + Trastuzumab rezetecanPhase 2HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Retlirafusp alfa + Zeprumetostat + Trastuzumab rezetecan + SHR-A1904Phase 2Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
HRS-4508Phase 2Lung Cancer
Est. primary completion 2027-12 · NCT07232849 · CT.gov ↗
What to watch
AdebrelimabPhase 2Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-12 · NCT07751341 · CT.gov ↗
What to watch
HRS-1893Phase 2Hypertrophic Cardiomyopathy
Est. primary completion 2027-12 · NCT07021963 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3Early-stage or Locally Advanced HER2-positive Breast Cancer
Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗
What to watch
Safiglipron (HRS-7535)Phase 3Hypertension With Overweight or Obesity
Est. primary completion 2027-12 · NCT07528027 · CT.gov ↗
What to watch
Notiretatug rezetecanPhase 3Recurrent Cervical Cancer, Metastatic Cervical Cancer
Est. primary completion 2027-12 · NCT07418749 · CT.gov ↗
What to watch
HRS-4357Phase 3PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2027-12 · NCT07311694 · CT.gov ↗
What to watch
2028 (33)
January 2028 (3)
SHR-3167Phase 3Diabetes Mellitus, Type 2
Est. primary completion 2028-01 · NCT07913061 · CT.gov ↗
What to watch
FelcorekibartPhase 3Asthma
Est. primary completion 2028-01 · NCT07098403 · CT.gov ↗
What to watch
Notiretatug rezetecan + AdebrelimabPhase 3Locally Advanced or Metastatic Urothelial Carcinoma
Est. primary completion 2028-01-31 · NCT07393542 · CT.gov ↗
What to watch
February 2028 (2)
ribupatidePhase 3Obesity, Overweight
Est. primary completion 2028-02 · NCT07284875 · CT.gov ↗
What to watch
vunakizumabPhase 3Active Non-radiographic Axial Spondyloarthritis
Est. primary completion 2028-02 · NCT06860750 · CT.gov ↗
What to watch
March 2028 (4)
SHR-2173Phase 2Systemic Lupus Erythematosus
Est. primary completion 2028-03 · NCT07299422 · CT.gov ↗
What to watch
ribupatidePhase 3Obesity
Est. primary completion 2028-03 · NCT07284979 · CT.gov ↗
What to watch
Adebrelimab + Trastuzumab rezetecanPhase 3PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
ribupatidePhase 3Obesity With Diabetes, Overweight With Diabetes
Est. primary completion 2028-03-27 · NCT07284901 · CT.gov ↗
What to watch
April 2028 (2)
AdebrelimabPhase 3Advanced Cervical Cancer
Est. primary completion 2028-04 · NCT07168200 · CT.gov ↗
What to watch
FelcorekibartPhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2028-04 · NCT07132827 · CT.gov ↗
What to watch
May 2028 (1)
Trastuzumab rezetecanPhase 2Advanced Colorectal Cancer Expressing HER2
Est. primary completion 2028-05-01 · NCT07796763 · CT.gov ↗
What to watch
June 2028 (3)
AdebrelimabPhase 2Resectable Non-small Cell Lung Cancer
Est. primary completion 2028-06 · NCT07704645 · CT.gov ↗
What to watch
Adebrelimab + Trastuzumab rezetecanPhase 2HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 2Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
September 2028 (1)
SHR-1703Phase 2Eosinophilic Asthma Patients
Est. primary completion 2028-09 · NCT06441812 · CT.gov ↗
What to watch
October 2028 (3)
Retlirafusp alfa + Notiretatug rezetecan + ZeprumetostatPhase 2Locally Advanced or Metastatic Non-small Cell Lung Cancer
Est. primary completion 2028-10 · NCT07175220 · CT.gov ↗
What to watch
AdebrelimabPhase 2/3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2028-10 · NCT06335355 · CT.gov ↗
What to watch
SHR-1819Phase 2/3Prurigo Nodularis
Est. primary completion 2028-10 · NCT06554509 · CT.gov ↗
What to watch
November 2028 (1)
SHR-4298Phase 1/2Malignant Solid Tumors
Est. primary completion 2028-11 · NCT07229612 · CT.gov ↗
What to watch
December 2028 (13)
SHR-6209 + HRS-6209 + HRS-8080 + HRS-6208Phase 1/2Advanced Unresectable or Metastatic Breast Cancer of Adults
Est. primary completion 2028-12 · NCT07389733 · CT.gov ↗
What to watch
HRS-8364Phase 1/2Solid Tumor
Est. primary completion 2028-12 · NCT07446153 · CT.gov ↗
What to watch
Notiretatug rezetecanPhase 2Advanced Solid Tumors
Est. primary completion 2028-12 · NCT06895928 · CT.gov ↗
What to watch
Adebrelimab + SHR-7787 + SHR-4849Phase 2Malignant Solid Tumors
Est. primary completion 2028-12 · NCT07268040 · CT.gov ↗
What to watch
Adebrelimab + SHR-7787Phase 2Limited-stage Small-cell Lung Cancer
Est. primary completion 2028-12 · NCT07798947 · CT.gov ↗
What to watch
Zeprumetostat + RezvilutamidePhase 2Prostate Cancer
Est. primary completion 2028-12 · NCT07230106 · CT.gov ↗
What to watch
SHR-4849Phase 2Malignant Solid Tumors
Est. primary completion 2028-12 · NCT07028281 · CT.gov ↗
What to watch
SHR-1703Phase 2/3Eosinophilic Granulomatosis With Polyangiitis
Est. primary completion 2028-12 · NCT05979051 · CT.gov ↗
What to watch
Dalpiciclib + HRS-8080Phase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2028-12 · NCT07354022 · CT.gov ↗
What to watch
HetrombopagPhase 3Patients With Chemotherapy-Induced Thrombocytopenia
Est. primary completion 2028-12 · NCT07286032 · CT.gov ↗
What to watch
Ruzaltatug rezetecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2028-12-30 · NCT07863167 · CT.gov ↗
What to watch
Ruzaltatug rezetecanPhase 3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2028-12-30 · NCT07895992 · CT.gov ↗
What to watch
Adebrelimab + HRS-4642Phase 1/2Pancreatic Cancer
Est. primary completion 2028-12-31 · NCT07806058 · CT.gov ↗
What to watch
2029 (15)
February 2029 (1)
FelcorekibartPhase 3Asthma
Est. primary completion 2029-02-15 · NCT07780643 · CT.gov ↗
What to watch
March 2029 (3)
FelcorekibartPhase 3Nasal Polyps
Est. primary completion 2029-03-06 · NCT07782957 · CT.gov ↗
What to watch
FelcorekibartPhase 3Nasal Polyps
Est. primary completion 2029-03-06 · NCT07782970 · CT.gov ↗
What to watch
FelcorekibartPhase 2Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-03-07 · NCT07915791 · CT.gov ↗
What to watch
April 2029 (2)
HRS-1780Phase 2/3Uncontrolled or Resistant Hypertension
Est. primary completion 2029-04 · NCT07708441 · CT.gov ↗
What to watch
HRS-4642Phase 3KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Est. primary completion 2029-04 · NCT07232875 · CT.gov ↗
What to watch
May 2029 (1)
FelcorekibartPhase 3Asthma
Est. primary completion 2029-05-04 · NCT07782996 · CT.gov ↗
What to watch
June 2029 (2)
Adebrelimab + Ruzaltatug rezetecan + Tizetatug rezetecanPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-06 · NCT06474455 · CT.gov ↗
What to watch
PlinabulinPhase 3Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
Est. primary completion 2029-06-01 · NCT07361484 · CT.gov ↗
What to watch
July 2029 (2)
FelcorekibartPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-07-20 · NCT07780656 · CT.gov ↗
What to watch
FelcorekibartPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-07-20 · NCT07780669 · CT.gov ↗
What to watch
September 2029 (1)
Trastuzumab rezetecanPhase 3Advanced Colorectal Cancer
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
December 2029 (3)
AdebrelimabPhase 3Advanced Biliary Tract Cancer
Est. primary completion 2029-12 · NCT07229625 · CT.gov ↗
What to watch
AdebrelimabPhase 3Locally Advanced Gastric or Gastroesophageal Junction Cancer
Est. primary completion 2029-12 · NCT07522151 · CT.gov ↗
What to watch
SHR-1501Phase 3Papillary-Only Non-muscle-invasive Bladder Cancer
Est. primary completion 2029-12 · NCT07726992 · CT.gov ↗
What to watch
2030 (9)
April 2030 (2)
Trastuzumab rezetecanPhase 3HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗
What to watch
HRS-1780Phase 3Chronic Kidney Disease
Est. primary completion 2030-04 · NCT07419828 · CT.gov ↗
What to watch
June 2030 (1)
SHR-1501Phase 3NMIBC
Est. primary completion 2030-06 · NCT07424287 · CT.gov ↗
What to watch
October 2030 (1)
Adebrelimab + Trastuzumab rezetecanPhase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
November 2030 (1)
Adebrelimab + HRS-4642Phase 3Systemic Treatment-naïve Pancreatic Cancer
Est. primary completion 2030-11-30 · NCT07900789 · CT.gov ↗
What to watch
December 2030 (4)
Adebrelimab + SHR-4610Phase 1/2Advanced Renal Cell Carcinoma
Est. primary completion 2030-12 · NCT07239596 · CT.gov ↗
What to watch
SHR-A1904Phase 2Biliary Tract Cancer
Est. primary completion 2030-12 · NCT07450976 · CT.gov ↗
What to watch
Adebrelimab + Trastuzumab rezetecanPhase 3Triple Negative Breast Cancer
Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗
What to watch
HRS-8080Phase 3Breast Cancer
Est. primary completion 2030-12 · NCT07349069 · CT.gov ↗
What to watch
2031 (7)
February 2031 (1)
Adebrelimab + Trastuzumab rezetecanPhase 3Non Small Cell Lung Cancer
Est. primary completion 2031-02 · NCT07896005 · CT.gov ↗
What to watch
May 2031 (1)
Safiglipron (HRS-7535)Phase 3Chronic Kidney Disease
Est. primary completion 2031-05 · NCT07625774 · CT.gov ↗
What to watch
July 2031 (1)
SHR-6209 + HRS-6209Phase 3Breast Cancer
Est. primary completion 2031-07-30 · NCT07894328 · CT.gov ↗
What to watch
September 2031 (1)
AdebrelimabPhase 3Hepatocellular Carcinoma
Est. primary completion 2031-09 · NCT07691762 · CT.gov ↗
What to watch
October 2031 (1)
AdebrelimabPhase 2Colorectal Cancer
Est. primary completion 2031-10 · NCT07071714 · CT.gov ↗
What to watch
December 2031 (2)
Notiretatug rezetecan + AdebrelimabPhase 2/3Muscular Invasive Bladder Cancer (MIBC)
Est. primary completion 2031-12 · NCT06879145 · CT.gov ↗
What to watch
Notiretatug rezetecan + AdebrelimabPhase 1/2Advanced Solid Tumors
Est. primary completion 2031-12-31 · NCT06417554 · CT.gov ↗
What to watch
2032 (2)
November 2032 (2)
AdebrelimabPhase 2/3Locally Advanced Resectable Rectal Cancer
Est. primary completion 2032-11 · NCT07454720 · CT.gov ↗
What to watch
Ruzaltatug rezetecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2032-11 · NCT07183189 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(19)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

9 April 2027FDA action dateCamrelizumabPDUFA target action date for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Source ↗

Recent

5 November 2026Filing acceptedCamrelizumabFDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC)
US, FDA · Source ↗
9 October 2026Filing submittedApatinibRivoceranib NDA resubmitted to the FDA after July 2026 CRL
US, FDA · Elevar Therapeutics, Inc. · Source ↗
24 September 2026Topline resultSHR-1701 (retlirafusp alfa)RELIGHT Phase 3 (NCT04950322) met its overall survival primary endpoint (full results in JCO)
China · Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Source ↗
2 September 2026Filing acceptedSafiglipron (HRS-7535)NMPA accepts Hengrui's marketing application for HRS-7535 tablets in type 2 diabetes
CN, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗
31 August 2026Topline resultHRS-5346Phase 2 study of oral HRS-5346 (NCT06816264) in adults at high cardiovascular risk with elevated Lp(a) presented at ESC 2026: HRS-5346 reduced Lp(a)
Jiangsu Hengrui Pharmaceuticals · Source ↗
28 August 2026Topline resultSHR-1918Phase 3 (NCT06723652) presented at ESC 2026: LDL-C 64.2% lower than placebo at week 12
24 August 2026Filing acceptedHRG2010NMPA accepts HRG2010 capsules marketing application (Parkinson's disease), based on Phase 3 HRG2010-301 (NCT06596876)
CN, NMPA · Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Source ↗
29 July 2026Filing acceptedSHR-A2009NMPA accepts the ruzaltatug rezetecan (SHR-A2009) marketing application in EGFR-mutated NSCLC after EGFR TKI; Phase 3 SHR-A2009-301 (NCT06671379) met its PFS primary
CN, NMPA · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (Hengrui subsidiary) · Source ↗
10 July 2026Complete response letterApatinibFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterCamrelizumabFDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗
2 July 2026Filing acceptedTrastuzumab rezetecanNMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review
China, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗
9 June 2026Filing acceptedSHR6508NMPA accepts the NDA for HS-10568 (SHR6508) in secondary hyperparathyroidism of CKD on hemodialysis
China, NMPA · Hansoh Pharmaceutical Group Company Limited · Source ↗

The 12 most recent of 18 past events are shown.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$1.2B$238M$5.9B—report ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$3.2B$691M$5.7B—report ↗
2025-H1$2.2B$445M$5.0B—report ↗
2024-Q3$2.8B$635M$3.2B—report ↗
2024-H1$1.9B$422M$3.1B—report ↗
2024-Q1$839M$171M$2.9B—report ↗
2023-Q3$2.4B$515M$2.4B—report ↗
2023-H1$1.6B$337M$2.2B—report ↗
2023-Q1$803M$168M$2.1B—report ↗
2022-Q3$2.3B$511M$2.2B—report ↗
2022-H1$1.6B$337M$2.0B—report ↗
2022-Q1$863M$159M$2.1B—report ↗
2021-Q3$3.1B$640M$2.2B—report ↗
2021-H1$2.1B$399M$1.5B—report ↗
2021-Q1$1.1B$203M$1.9B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.7B$1.0B——report ↗

Hengrui Pharmaceuticals reported revenue of $4,669M, up 19.9% YoY, with R&D spend of $1,027M, up 12.1% YoY. Net profit attributable to shareholders reached RMB 7.72 billion, up 21.8% YoY; cash and equivalents were not disclosed.

The company guided for approximately 53 innovative product and indication approvals anticipated during 2026-2028. In 2025 it secured seven Class 1 innovative drug approvals, one Class 2 approval, and six new indications, while 15 NDAs/BLAs were accepted and over 100 proprietary innovative products are in clinical development. Key events included five overseas business development deals, a strategic collaboration with GSK, and a Hong Kong listing raising HK$11.4 billion.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.9B$916M$3.4B—report ↗
2023-FY$3.2B$701M$2.9B—report ↗
2022-FY$3.2B$728M$2.2B—report ↗
2021-FY$4.0B$921M$2.1B—report ↗